LABA medications provide sustained bronchodilation over a 12- to 24-hour period after delivery. For the treatment of asthma, they are supplied in combination with an inhaled steroid medication via a metered dose inhaler or dry powder inhaler. Children with intermittent asthma have only occasional need for bronchodilators and do not benefit from the use of LABAs on a daily basis. Children with mild persistent asthma are usually well-controlled with a single agent – either a leukotriene modifier or a low-dose inhaled corticosteroid medication. The addition of a LABA is not recommended in these circumstances and should be reserved for children with moderate persistent or severe persistent asthma.